Search All Jobs

Showing 1 of 1 Jobs

Manager – Government Pricing

$102.9k - $135k/yr

Remote in USA

Full-Time

Manager – Government Pricing

Confirmed live in the last 24 hours

Model N

Model N

1,001-5,000 employees

Cloud-based revenue management solutions provider

Compensation Overview

$102.9k - $135k/yr

+ Bonus + Commission

Senior, Expert

Remote in USA

Category
Financial Analysis
Governmental Accounting
Accounting
Required Skills
Excel/Numbers/Sheets
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Model N referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s Degree required in finance, accounting, or other applicable business experience.
  • 8+ years’ experience working in the pharmaceutical industry working with state and federal pricing, reporting, and rebate programs, is required.
  • Strong written and verbal communication skills.
  • High accuracy rate and attention to detail; ability to produce client-ready deliverables to a high-level executive/professional client base.
  • Experience with Microsoft Office products required and knowledge of advance Excel techniques such as pivot tables and data importing are desired.
Responsibilities
  • Manage ongoing client relationships (interface w/ clients to resolve specific issues)
  • Review and approve all client billings.
  • Calculate and file appropriate prices for the federal drug programs. Prices include, BP, AMP, ASP, PHS/340B, NFAMP, FCP/FSS, IFF, and URA.
  • Ability to handle complex Government Pricing concepts such as bundles, discount reallocation, pro-ration and smoothing.
  • Lead, review and approve price calculation reporting with client.
  • Oversee the analysis and review of the monthly and quarterly source data reconciliation and sales data used in price reporting calculations and ensure reports are submitted in accordance with government regulations.
  • Responsible for maintaining valid customer Class of Trades assignments in accordance with regulations.
  • Ensure that 340B/PHS prices are calculated, available for pricing and maintained per the federal regulation.
  • Lead client price calculation and/or restatement efforts, as needed.
  • Lead, manage, mentor, and develop government program Analysts.
  • Stay current and provide business guidance internally and to customers related to the life science’s Commercial and/or regulatory landscape.
  • Expected to continually build detailed subject matter expertise and thought leadership in area of government program regulations and share this knowledge with direct reports and peer groups.
Desired Qualifications
  • Experience in working in mandated deadline environment; effective in managing multiple client assignments; ability to prioritize.
  • Experience in and ability to learn standard industry systems environment.
  • Able to manage multiple and competing tasks across functional areas is essential.
  • Experience achieving and maintaining compliance with all applicable regulatory, legal, and operational rules and procedures by ensuring that all plans and activities are met with “best” industry practices.

Model N provides cloud-based revenue management solutions specifically designed for the high-tech and life sciences industries. Their platform assists clients in maximizing revenue throughout the commercialization process, which includes improving the quote-to-cash process and enhancing relationships with channel partners. Model N's solutions, such as Revenue Cloud for Pharma, Medtech, and High Tech, address the unique pricing and compliance challenges faced by these sectors, helping companies manage global pricing and tender management effectively. Unlike many competitors, Model N operates on a software-as-a-service (SaaS) model, allowing clients to subscribe for ongoing access to their tools and services, which ensures regular updates and support. The company's goal is to help clients bring life-changing products to market more efficiently while navigating regulatory changes, ultimately generating significant savings for their customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Mateo, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Model N's GenAI integration enhances data processing and compliance capabilities.
  • The Inflation Reduction Act drives demand for advanced rebate management solutions.
  • Vista Equity Partners' acquisition could accelerate product development and market expansion.

What critics are saying

  • Vista's acquisition may disrupt existing client relationships or alter company focus.
  • New AI capabilities may face adoption challenges if clients aren't ready for advanced tech.
  • Inflation Reduction Act could lead to revenue adjustments for pharmaceutical clients.

What makes Model N unique

  • Model N specializes in revenue management for life sciences and high-tech industries.
  • Their solutions address complex pricing, compliance, and revenue challenges in these sectors.
  • Model N's SaaS model ensures continuous updates and support for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Paid Vacation

Life Insurance

Pet Insurance

Employee Assistance Programs

Mental Health Support

Employee Stock Purchase Plan

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Hit Consultant
Jan 17th, 2025
Recent Digital Health Executive Hires And Promotions: Medidata Expands Team, Carerev, Philips, Eko Health, Others

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

MarketScreener
Jan 6th, 2025
Model N Appoints Bret Connor as Chief Executive Officer

Model N has appointed Bret Connor as Chief Executive Officer.

Hit Consultant
Jan 6th, 2025
Model N Appoints Bret Connor As Ceo To Drive Next Phase Of Growth

Model N Appoints Bret Connor as CEO to Drive Next Phase of Growth. by Healthcare Executive Hires 01/06/2025 Leave a Comment. Bret Connor, CEO at Model NWhat You Should Know: – Model N, a leading provider of revenue optimization and compliance solutions for life sciences and high-tech companies, announced the appointment of Bret Connor as Chief Executive Officer. – Connor brings a wealth of experience in driving customer success and operational excellence, positioning Model N for continued growth and market leadership.  Bret Connor Bio/BackgroundConnor joins Model N from athenahealth, where he served as Chief Operating Officer. During his tenure, he played a key role in the company’s transition to private ownership and spearheaded initiatives focused on client satisfaction and operational excellence. Under his leadership, athenahealth achieved record-high Net Promoter Scores and client retention rates, culminating in a successful recapitalization for $17 billion in 2022. He previously held executive roles at VMware, leading their Professional Services business in the Americas

PharmiWeb
Nov 20th, 2024
Model N Introduces Genai And Intelligent Data Innovations To Market-Leading Revenue Optimization And Compliance Offering

Latest innovations leverage GenAI and enriched data to strengthen global expansion, compliance, and channel sales.SAN MATEO, Calif. – November 20, 2024 – Model N, the leader in revenue optimization and compliance for life sciences and high-tech companies, launched new generative AI (GenAI) and expanded data capabilities to strengthen its core product suite. Integrating GenAI and intelligent data into the company’s Channel Data Management, Formulary Compliance, and Provider Management solutions showcases Model N's strong commitment to delivering continuous innovation and excellence to the world’s most innovative brands in life sciences and high tech.“The opportunity to harness the power of GenAI and intelligent data to help our customers drive revenue growth, strengthen compliance, and achieve market success couldn’t be greater. As we look ahead, continuing to innovate with AI technologies in our product portfolio remains a top priority – empowering our customers to deliver life-changing products,” said Suresh Kannan, Chief Product Officer, Model N.Bolstering Channel Sales by Leveraging GenAIModel N’s new generative AI Catalog Discovery is a part of its Channel Data Management solution that effectively helps high tech companies manage revenue from indirect sources. GenAI Catalog Discovery automates point-of-sale (POS) data processing, converting unstructured product descriptions into structured, actionable data, regardless of language. High-tech manufacturers can use the AI output to identify how their products are used and bundled for consumption

PharmiWeb
May 9th, 2024
Model N Introduces New Rebate Enhancement, As Pharma Companies Prepare For Impact From The Inflation Reduction Act

Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact from the Inflation Reduction ActNew Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reformsModel N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss."The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates.”According to Model N’s 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA. The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025. Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a unified, end-to-end process to manage pricing strategy, calculate fees, and issue rebate payments in compliance with IRA guidance.The company is committed to ensuring that pharma customers are equipped with the most up-to-date technology to comply with IRA guidance, which will continue to evolve into 2026